Paula Pecen is an Ophthalmology physician. OpenAlex indexes 49 publications with 986 citations (h-index 16).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Industry payments
18 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alcon Vision LLCProgram year20253 payments
- Harrow Eye, LLCProgram year20252 payments
- ABBVIE INC.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
98.7%Antineovascularisation agents97.2%Faricimab-svoa100%Part B, office-administered≥89 patientsCorticosteroid0.6%Prednisolone Acetate100%Part D≥117 patients+ 5 more classes in this area
Cancer & immunology
1.2%Vascular Endothelial Growth Factor Inhibitor1.2%Aflibercept51%Bevacizumab49%Part B, office-administered≥61 patientsMusculoskeletal
0.1%Cyclooxygenase Inhibitor0.1%Ketorolac Tromethamine100%Part D≥14 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Immunomodulatory Therapy Discontinuation for Reasons Other Than Efficacy in the Treatment of Ocular Inflammation
Ocular Immunology and Inflammation
2025 - Cytomegalovirus Retinitis in the Modern Era of Solid Organ Transplantation
Transplantation Proceedings
2024 - Short-acting Corticosteroid Injections Predict the Response to Fluocinolone Implant
Ophthalmology Retina
2023 - Evaluation of the SUN Classification Criteria for Uveitides in an Academic Uveitis Practice
American Journal of Ophthalmology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Emily Chew, MD
National Eye Institute
Robert Weinreb, MD
University of California San Diego
Harry Quigley, MD
Johns Hopkins University School of Medicine
Joel Schuman, MD
Wills Eye Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”